Third consensus document on the use of antimicrobial agents in chronic obstructive pulmonary disease exacerbations;Tercer documento de consenso sobre el uso de antimicrobianos en la agudización de la enfermedad pulmonar obstructiva crónica

Revista Espanola de Quimioterapia

Volumn 20, Issue 1, 2007, Pages 93-105

  Garcia Rodriguez J A ^a   Mensa, J ^a   Picazo, J J ^a   Miravitlles, M ^a   Monso E ^a   Moya Mir, M S ^a   Martinez Ortiz De Zarate M ^a   Barcena Caamano M ^a   Aguaron Perez J ^a   Canada Merino J L ^a   Quintano Jimenez J A ^a   Barberan J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFDITOREN; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GLUCOCORTICOID; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONSENSUS; EPIDEMIOLOGICAL DATA; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; MORAXELLA CATARRHALIS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; HOSPITALIZATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TERMINOLOGY;

EID: 34250890795     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (95)

1. Peces-Barba, G., Barberá, J.A., Agustí, A. y cols. Guía clínica de diagnóstico y tratamiento de la EPOC, SEPAR-ALAT 2007. Arch Bronconeumol 2007; en prensa.
2. Snider, G.L., Kleinreman, J., Thurlbeck, W.M., Bengali, Z.H. The definition of emphysema: Report of the National Heart and Blood Institute, division of lung diseases, workshop. Am Rev Respir Dis 1985; 132: 182-185.
3. Frías, J., Gomis, M., Prieto, J. y cols. Tratamiento antibiótico empírico initial de la neumonía adquirida en la comunidad. Rev Esp Quimioterap 1998; 11: 255-261.
4. Alfageme, I., Aspa, J., Bello, S. y cols. Normativa para el diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol 2005; 41: 272-289.
5. Miravitlles, M., Morera, J. It's time for an etiology-based definition of chronic obstructive pulmonary disease. Respirology 2007; en prensa.
6. Sobradillo, V., Miravitlles, M., Gabriel, R. y cols. Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC Multicentre Epidemiological Study. Chest 2000; 118: 981-989.
7. De Marco, R., Accordini, S., Cerveri, I. y cols. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125.
8. Jemal, A., Ward, E., Hao, Y., Thun, M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259.
9. Ballester, F., Pérez-Hoyos, S., Rivera, M.L. y cols. Patrones de frecuentación y factores asociados al ingreso en el hospital de las urgencias hospitalarias por asma y enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 1999; 35: 20-26.
10. Grupo para el Estudio de la Infección en Urgencias. Estudio epidemiológico de las infecciones en el Área de Urgencias. Emergencias 2000; 12: 80-89.
11. Martínez Ortiz, de Zárate, M. Aspectos epidemiológicos de las infecciones en las Áreas de Urgencias. Emergencias 2001; 13 (Supl. 2): S44-S50.
12. MacFarlane, J.T., Colville, A., Guion, A., MacFarlane, R.M., Rose, D.H. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993; 341: 511-514.
13. Miravitlles, M., Mayordomo, C., Artés, M. y cols., on behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999; 93: 173-179.
14. Woodhead, M., Gialdroni Grassi, G., Huchon, G.J. y cols. Use of investigations in lower respiratory tract infection in the community: A European survey. Eur Respir J 1996; 9: 1596-1600.
15. Romero Vivas, J., Rubio Alonso, M., Corral, O. y cols. Estudio de las infecciones respiratorias extrahospitalarias. Enferm Infecc Microbiol Clin 1997; 15: 289-298.
16. Llor, C., Cots, J.M., Boada, A. y cols., y grupo de estudio AUDIT-INF02. Variabilidad de la prescripción antibiótica en las infecciones respiratorias en dos países de Europa. Enferm Infecc Microbiol Clin 2005; 23: 598-604.
17. Papi, A., Bellettato, C.M., Braccioni, F. y cols. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121.
18. Miravitlles, M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 2002; 9: 191-197.
19. Soler, N., Torres, A., Ewig, S. y cols. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-1505.
20. Rhode, G., Wiethege, A., Borg, I. y cols. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: A case-control study. Thorax 2003; 58: 37-42.
21. Mogulkoc, N., Karakurt, S., Isalska, B. y cols. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160: 349-353.
22. Donaldson, G.C., Seemungal, T., Jeffries, D.J., Wedzicha, J.A. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 844-849.
23. García-Aymerich, J., Tobías, A., Anto, J.M., Sunyer, J. Air pollution and mortality in a cohort of patients with chronic obstructive pulmonary disease: A time series analysis. J Epidemiol Community Health 2000; 54: 73-74.
24. Burrows, B., Bloom, J.W., Traver, G.A., Cline, M.G. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
25. Pauwels, R.A., Buist, A.S., Calverley, P.M.A., Jenkins, C.R., Hurd, S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
26. Miravitlles, M., Fernández, I., Guerrero, T., Murio, C. Desarrollo y resultados de un programa de cribado de la EPOC en Atención Primaria. El proyecto PADOC. Arch Bronconeumol 2000; 36: 500-505.
27. Postma, D.S. When can an exacerbation of COPD be treated at home? Lancet 1998; 351: 1827-1828.
28. Niewoehner, D.E., Erbland, M.L., Deupree, R.H. y cols. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-1947.
29. Mahler, D.A., Rosiello, R.A., Harver, A. y cols. Comparison of clinical dysnea ratings and psychophysical measurements of respiratory sensation in obstructive airways disease. Am Rev Respir Dis 1987; 165: 1229-1233.
30. Duffy, N., Walker, P., Diamantea, F., Calverley, P.M., Davies, L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Thorax 2005; 60: 713-717.
31. Connors, A.F.J., Dawson, N.V., Thomas, C. Outcomes following acute exacerbations of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154: 959-996.
32. Moya Mir, M.S., Laguna del Estal, P., Salgado Marqués, R., Calabrese Sánchez, S. Infección respiratoria en observación de urgencias. Emergencias 1997; 9: 98-102.
33. Murata, G.H., Gorby, M.S., Chick, T.W., Halperin, A.K. Use of emergency medical services by patients with decompensated obstructive lung disease. Ann Emerg Med 1989; 18: 501-506.
34. Emerman, C.L., Effron, D., Lukens, T.W. Spirometric criteria for hospital admission of patients with acute exacerbation of COPD. Chest 1991; 99: 595-599.
35. Kessler, R., Faller, M., Fourgaut, G., Mennecier, B., Weitzenblum, E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158-164.
36. Monsó, E., Ruiz, J., Rosell, A. y cols. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated out-patients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-1320.
37. Rosell, A., Monso, E., Soler, N. y cols. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891-897.
38. Zalacain, R., Sobradillo, V., Amilibia, J. y cols. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 343-348.
39. Miravitlles, M. Exacerbations of chronic obstructive pulmonary disease: When are bacteria important? Eur Respir J 2002; 20 (Suppl. 36): 9-19.
40. Miravitlles, M., Espinosa, C., Fernández-Laso, E. y cols. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-46.
41. Eller, J., Ede, A., Schaberg, T. y cols. Infective exacerbations of chronic bronchitis. Relation between bacleriologic etiology and lung function. Chest 1998; 113: 1542-1548.
42. Monsó, E., García-Aymerich, J., Soler, N. y cols. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 2003; 131: 799-804.
43. Fagon, J.Y., Chastre, J., Trouillet, J.L. y cols. Characterization of distal bronchial microflora during acute exacerbations of chronic bronchitis: Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 1004-1008.
44. Thornsberry, C., Sahm, D.F. Antimicrobial resistance in respiratory tract pathogens: Results of an international surveillance study. Chemotherapy 2000; 46 (Suppl. 1): 15-23.
45. Baquero, F., García-Rodríguez, J.A., García de Lomas, J., Aguilar, L., The Spanish Surveillance Group. Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1 year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother 1999; 43: 357-359.
46. Heffelfinger, J.D., Dowell, S.F., Jorgensen, J.H. y cols. Management of community acquired pneumonia in the era of pneumococcal resistance: A report from drug-resistant Streptococcus pneumoniae. Therapeutic Working Group. Arch Intern Med 2000; 160: 1339-1408.
47. Dewan, N.A., Rafique, S., Kanwar, B. y cols. Acute exacerbation of COPD. Factors associated with poor outcome. Chest 2000; 117: 662-671.
48. Adams, S.G., Melo, J., Luther, M., Anzueto, A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-1352.
49. Miravitlles, M., Murio, C., Guerrero, T. on behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J 2001; 17: 928-933.
50. Murray, T.J., Washington, J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975; 50: 339-344.
51. Stockley, R.A., O'Brien, C., Pye, A., Hill, S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645.
52. Soler, N., Agustí, C., Angrill, J., Puig de la Bellacasa, J., Torres, A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29-35.
53. Allegra, L., Blasi, F., Diano, P. y cols. Sputum color as a marker of acute exacerbations of chronic obstructive pulmonary disease. Respir Med 2005; 99: 742-747.
54. Odenholt, I., Cars, O., Lowdin, E. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: Comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens. J Antimicrob Chemother 2004; 54: 1062-1066.
55. Soriano, F., Granizo, J.J., Fenoll, A. y cols. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: Results from the cefditoren surveillance program. J Chemother 2003; 15: 107-112.
56. Soriano, F., Granizo, J.J., Coronel, P. y cols. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory-tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents 2004; 23: 296-299.
57. Eiros Bouza, J.M., Valdés, L., Bachiller, M.R. Contribución de la farmacodinamia en la elección del antimicrobiano para las exacerbaciones de la EPOC. Rev Esp Quimioterap 2006; 19: 220-230.
58. Liñares, J., Alonso, T., Pérez, J.L. y cols. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. J Antimicrob Chemother 1992; 30: 279-288.
59. Miravitlles, M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005; 6: 283-293.
60. Mensa, J., Trilla, A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin Microbiol Infect 2006; 12 (Suppl. 3): 42-54.
61. Miravitlles, M., Martín Graczyk, A. Tratamiento del paciente con EPOC agudizada. Guía de buena práctica clínica en geriatría. Enfermedad Pulmonar Obstructiva Crónica. Normativa conjunta SEPAR-SEGG (Sociedad Española de Geriatría y Gerontología). Elsevier Farma, Barcelona 2006; 75-88.
62. Gotfried, M.H., Danzinger, L.H., Rodvold, K.A. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119: 1114-1122.
63. Wilson, R., Allegra, L., Huchon, G. y cols. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.
64. Niederman, M.S., Anzueto, A, Sethi, S. y cols. Eradication of Haemophilus influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 2006; 100: 1781-1790.
65. Pérez-Trallero, E., García de la Fuente, C., García-Rey, C. y cols. Geographical and ecological analysis of resistance, coresistance, and coupledresistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-1972.
66. Sethi, S., Anzueto, A., Farrell, D.J. Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3043 patients with acute exacerbation of chronic bronchitis. Ann Clin Microbiol Antimicrob 2005; 4: 5-11.
67. Clay, K.D., Hanson, J.S., Pope, S.D. y cols. Brief communication. Severe hepatotoxicity of telithromycin: Three case reports and literature review. Ann Intern Med 2006; 144: 415-420.
68. Sethi, S., Breton, J., Wynne, B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 2005; 49: 153-160.
69. Álvarez-Sala, J.L., Kardos, P., Martínez-Beltrán, J., Coronel, P., Aguilar, L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762-1767.
70. Amsden, G.W., Baird, I.M., Simon, S., Treadway, G. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772-777.
71. Chodosh, S., DeAbate, C.A., Haverstock, D., Aneiro, L., Church, D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000; 94: 18-27.
72. Wilson, R., Kubin, R., Ballin, I. y cols. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-513.
73. Fogarty, C., De Wet, R., Mandell, L. y cols. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005; 128: 1980-1988.
74. Bouza, E., García-Garrote, F., Cercenado, E., Marín, M., Díaz, M.S. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother 1999; 43: 981-982.
75. MacGowan, A.P., Wootton, M., Holt, H.A. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999; 43: 345-349.
76. Madaras-Kelly, K.J., Ostergaard, B.E., Hovde, L.B., Rotschafer, J.C. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40: 627-632.
77. Miravitlles, M., Anzueto, A., Legnani, D., Forstmeier, L., Fargel, M. Patient's perception of exacerbations of COPD - The PERCEIVE study. Respir Med 2007; en prensa.
78. Scott, S., Walker, P., Calverley, P.M.A. COPD exacerbations. 4: Prevention. Thorax 2006; 61: 440-447.
79. Murphy, T.F. Haemophilus influenzae in chronic bronchitis. Semin Respir Infect 2000; 15: 41-51.
80. Foxwell, A.R., Cripps, A.W. Haemophilus influenzae oral vaccination against acute bronchitis. Cochrane Database Syst Rev 2000; CD001958.
81. Rodrigo, M.J., Vendrell, M., Cruz, M.J. y cols. Utility of the antibody response to a conjugated H. influenzae type b vaccine for diagnosis of primary humoral immunodeficiency. Am J Respir Crit Care Med 2000; 162: 1462-1465.
82. Kyd, J.M., Dunkley, M.L., Cripps, A.W. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 1995; 63: 2931-2940.
83. Jackson, L.A., Neuzil, K.M., Yu, O. y cols. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-1755.
84. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46: 1-24.
85. Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rev 1999; 74: 177-183.
86. British Thoracic Society. Chronic obstructive pulmonary disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl. 1): i39-i130.
87. Vila-Córcoles, A., Ochoa-Gondar, O., Llor, C. y cols. Protective effect of pneumococcal vaccine against death by pneumonia in elderly-subjects. Eur Respir J 2005; 26: 1086-1091.
88. Alfageme, I., Vázquez, R., Reyes, N. y cols. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189-195.
89. Seemungal, T.A.R., Harper-Owen, R., Bhowmik, A., Jeffries, D.J., Wedzicha, J.A. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000; 16: 677-683.
90. Mallia, P., Johnston, S.L. How viral infection cause exacerbation of airway diseases. Chest 2006; 130: 1203-1210.
91. Poole, P.J., Chacko, E., Wood-Baker, R.W.B., Cates, C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease (Cochrane review), vol. 1. Cochrane Library, Oxford, Update Software 2001.
92. Steurer-Stey, C., Bachmann, L.M., Steurer, J., Tramèr, M.R. Oral purified bacterial extracts in chronic bronchitis and COPD. Chest 2004; 126: 1645-1655.
93. Prieto, A., Reyes, E., Bernstein, E.D. y cols. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med 2001; 163: 1578-1583.
94. Reyes, E., Prieto, A., De la Hera, A. y cols. Treatment with AM3 restores defective T-cell function in COPD patients. Chest 2006; 129: 527-535.
95. Álvarez-Mon, M., Miravitlles, M., Morera, J., Callol, L., Álvarez-Sala, J.L. Treatment with the immunomodulator AM3 (Inmunoferon) improves the health-related quality of life of patients with chronic obstructive pulmonary disease. Chest 2005; 127: 1212-1218.